Xencor, Inc. (NASDAQ:XNCR – Get Rating) – Research analysts at SVB Leerink decreased their Q3 2022 earnings per share (EPS) estimates for Xencor in a report issued on Thursday, August 4th. SVB Leerink analyst J. Chang now forecasts that the biopharmaceutical company will post earnings of ($0.95) per share for the quarter, down from their prior estimate of ($0.84). The consensus estimate for Xencor’s current full-year earnings is ($1.76) per share. SVB Leerink also issued estimates for Xencor’s Q4 2022 earnings at ($1.01) EPS, FY2022 earnings at ($2.12) EPS and FY2023 earnings at ($1.77) EPS.
Xencor (NASDAQ:XNCR – Get Rating) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of ($0.70) by $1.09. The business had revenue of $85.50 million during the quarter, compared to the consensus estimate of $26.17 million. Xencor had a return on equity of 3.15% and a net margin of 7.77%. The business’s quarterly revenue was up 152.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.04) EPS.
Several other analysts have also recently commented on XNCR. Piper Sandler dropped their price target on Xencor from $66.00 to $42.00 and set an “overweight” rating for the company in a research report on Monday, May 23rd. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $50.00 price target on shares of Xencor in a research report on Wednesday, July 6th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.83.
Xencor Price Performance
Ad Investing Daily
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Shares of XNCR stock opened at $29.34 on Monday. The company has a market cap of $1.75 billion, a price-to-earnings ratio of 86.30 and a beta of 0.61. The stock has a 50 day simple moving average of $26.74 and a 200-day simple moving average of $27.84. Xencor has a 1-year low of $19.35 and a 1-year high of $43.61.
Hedge Funds Weigh In On Xencor
A number of hedge funds have recently modified their holdings of the business. MQS Management LLC purchased a new position in shares of Xencor during the 2nd quarter worth $201,000. State of New Jersey Common Pension Fund D grew its holdings in shares of Xencor by 26.6% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 96,463 shares of the biopharmaceutical company’s stock worth $2,640,000 after purchasing an additional 20,266 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of Xencor by 27.1% during the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,392 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 2,214 shares during the period. Jackson Creek Investment Advisors LLC purchased a new position in shares of Xencor during the 2nd quarter worth $1,076,000. Finally, Nisa Investment Advisors LLC purchased a new position in shares of Xencor during the 2nd quarter worth $27,000. 98.43% of the stock is currently owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xencor, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Xencor wasn’t on the list.
While Xencor currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
